Cargando…
Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
The use of CDK4/6 inhibitors in the treatment of a wide range of cancers is an area of ongoing investigation. Despite their increasing clinical use, there is limited understanding of the determinants of sensitivity and resistance to these drugs. Recent data have cast doubt on how CDK4/6 inhibitors a...
Autores principales: | Pennycook, Betheney R., Barr, Alexis R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596008/ https://www.ncbi.nlm.nih.gov/pubmed/34784791 http://dx.doi.org/10.1098/rsob.210125 |
Ejemplares similares
-
Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma
por: Chen, Tingting, et al.
Publicado: (2021) -
Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breast cancer cells
por: Blain, Stacy W.
Publicado: (2018) -
Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27
por: Coulonval, Katia, et al.
Publicado: (2021) -
Gatifloxacin Induces S and G(2)-Phase Cell Cycle Arrest in Pancreatic Cancer Cells via p21/p27/p53
por: Yadav, Vikas, et al.
Publicado: (2012) -
P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
por: Li, Paiyun, et al.
Publicado: (2019)